Diligence memo · auto-generated · as of July 2, 2026

X1 Biotech Inc.

X1 Biotech Inc. looks under-valued against its niche peers and is at-risk on financing cadence.

WatchOverdue for a raise versus sector cadence — could be a bridge, a down round, or distress. Watch for the next filing.

Businessfiled

X1 Biotech Inc. operates in Biotech, based in NEEDHAM.

Sub-sector tags: biotech.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

X1 Biotech Inc. has raised $100K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).

Largest single filing: $100K on 2023-11-07.

Most recent recorded round closed around 2023-11-07.

Valuation (modeled)modeled

Provath models X1 Biotech Inc. at approximately $691K (range $53K–$2.8M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.38× the median modeled value of Pre-Seed Biotech companies in 2022–2024 (5 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Last raise 2.7 yr ago; this sector typically re-raises about every 11 months.

Past due for a raise versus sector cadence — watch for distress or a bridge.

Comparablesmixed

Capital scale ranks ahead of 68% of Biotech peers (233 compared).

Modeled value ranks above 68% of those peers.

Closest niche peers: Antlia Bioscience, Inc., Innovation1 Biotech Inc., Bodhi Tree Biotechnology Inc, Biotech Social Inc..

Peoplefiled

5 named people on file across officers, directors and signatories.

Risks & flagsmixed

Overdue for a raise versus sector norm — distress or bridge risk.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.